Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

QR Code

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Michael B Horsley, Malik Y Kahook
Format:	article
Language:	EN
Published:	Dove Medical Press 2009
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
by: Schmier JK, et al.
Published: (2014)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
by: Takagi Y, et al.
Published: (2018)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
by: Jordana K Schmier, et al.
Published: (2010)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
by: Anne J Lee, et al.
Published: (2010)

Quality of life of glaucoma patients under medical therapy with different prostaglandins
by: Paletta Guedes RA, et al.
Published: (2012)

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
by: Oghenowede Eyawo, et al.
Published: (2009)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
by: Lorenz K, et al.
Published: (2011)

Challenges in the clinical measurement of ocular surface disease in glaucoma patients
by: Pflugfelder SC, et al.
Published: (2011)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
by: Tamçelik N, et al.
Published: (2017)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
by: Hommer A, et al.
Published: (2011)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
by: Kenji Inoue, et al.
Published: (2011)

Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid
by: Lawrence Y Ho, et al.
Published: (2008)

A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma
by: Garcia-Fejioo J, et al.
Published: (2012)

Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
by: Cvenkel B, et al.
Published: (2015)

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
by: Fukuda M, et al.
Published: (2013)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
by: Costa VP, et al.
Published: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
by: Gregory Katz, et al.
Published: (2010)

First-year treatment costs among new initiators of topical prostaglandin analogs
by: Jordana K Schmier, et al.
Published: (2009)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
by: Inoue K, et al.
Published: (2012)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
by: Ruangvaravate N, et al.
Published: (2020)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
by: Seibold LK, et al.
Published: (2014)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
by: Radcliffe NM
Published: (2014)

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
by: Jordana K Schmier, et al.
Published: (2010)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
by: Masahiko Ayaki, et al.
Published: (2010)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
by: Lo JS, et al.
Published: (2016)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
by: Mizoguchi T, et al.
Published: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
by: Lanzl I, et al.
Published: (2013)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
by: Anna Galanopoulos, et al.
Published: (2008)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
by: Figueiredo BP, et al.
Published: (2013)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
by: Mylla Boso AL, et al.
Published: (2020)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
by: Scott D Smid
Published: (2009)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue K, et al.
Published: (2012)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
by: Shimizu Y, et al.
Published: (2015)

Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients
by: Adam M Moss, et al.
Published: (2010)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
by: Dimitris Papaconstantinou, et al.
Published: (2009)

Ocular surface disease in posttrabeculectomy/mitomycin C patients
by: Lam J, et al.
Published: (2015)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
by: Sophia K Mirza, et al.
Published: (2010)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
by: Pacella F, et al.
Published: (2012)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
by: Emilio Rintaro Suzuki Jr, et al.
Published: (2010)

Patient satisfaction with glaucoma therapy: reality or myth?
by: Lemij HG, et al.
Published: (2015)